Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection

Social and Economic Burden of Human Leishmaniasis

“…Studies have shown that encapsulation of antigens in liposomes, nanoparticles, or inclusion of adjuvants greatly enhances their immunogenicity and protective ability, [33][34][35] thus underscoring the need for continued studies in improving vaccine delivery. The development of a vaccine will benefit an estimated 350 million people who are at risk of developing the disease worldwide.…”

Biomaterials for Nanoparticle Vaccine Delivery Systems

“…Formed by either high-pressure homogenization of lipid molecules or microemulsion technique, these solid lipid nanoparticles offer opportunities to sustain release of lipophilic and hydrophilic drugs. Cationic solid lipid nanoparticles (cSLN) capable of adsorbing negatively charged DNA have been recently developed for delivery of coding sequences for three different types of cysteine proteinases in Leishmania major (54). These lipid-based nanoparticles effectively protected the cargo from nucleases in vitro , and particles with ~250 nm diameter and positive zeta potential enhanced DC targeting, phagocytosis, and transfection efficiency.…”

Combining Cationic Liposomal Delivery with MPL-TDM for Cysteine Protease Cocktail Vaccination against Leishmania donovani : Evidence for Antigen Synergy and Protection

“…The pellet containing inclusion bodies was solubilised with solublization buffer [50 mM CAPS {3-(Cyclohexylamino)-1-propanesulfonic acid} buffer (pH 11.0), 300 mM NaCl, and 0.5% sarkosyl], kept at room temperature for 30 min and finally centrifuged at 12,000× g for 30 min at 4°C. The supernatant containing solubilised proteins were loaded separately onto Ni 2+ -nitrilotriacetic acid-agarose (Ni-NTA) column (Qiagen) and purified under denaturing conditions [16]. The Ni-NTA column was pre equilibriated with equilibriation buffer [50 mM CAPS buffer (pH 11.0), 150 mM NaCl, 0.5% sarkosyl and 10 mM imidazole].…”

“…Further, CPs are established virulence factors involved in parasitic survival, autophagy and metacyclogenesis essential for onset of the disease and are being increasingly exploited as serodiagnostic markers, drug targets and vaccine candidates against Leishmania [13], [14]. Protein and DNA vaccine attempts using CPA, CPB and CPC in different adjuvants have been reported against L. major [15], [16] and L. infantum [17] in mice and canine models [18]. However, these research efforts have been largely restricted to cutaneous and zoonotic VL with variable success rate but have never been investigated against L. donovani , the causative agent of kala-azar.…”